U.S. FDA to review fewer emergency use requests for COVID tests
Reuters
Published Sep 27, 2022 11:03AM ET
Updated Sep 27, 2022 04:01PM ET
(Reuters) - The U.S. Food and Drug Administration said on Tuesday it will now review only a small number of emergency use authorization requests for COVID tests that are likely to have a significant benefit to public health, including fulfilling an unmet need.
The agency is revising its COVID-19 test policy in light of the current manufacturing status and number of cases, it said, adding companies seeking EUA for their COVID tests will have to now apply for the agency's traditional premarket review process.
"Taking into account the current status of manufacturing capacity and consumer access...shifting to traditional premarket review would best meet the public health needs at the current stage of the COVID-19 public health emergency," FDA official Jeff Shuren said in a statement.
Last week, federal investigators found that the regulator's decision to accept all EUA requests in the early months of the pandemic resulted in some 'problematic tests on the market' and recommended the FDA revise its EUA policies for the tests.
To date, more than 430 distinct COVID-19 tests have been issued EUAs. The FDA did not immediately respond to Reuters request for comment on the status of these tests after Tuesday's policy revision.
The FDA said on Tuesday it will also focus on supplemental requests for previously authorized tests, or those funded by a federal agency.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.